- ¿Vacuna contra el hantavirus en 2026?2¢2 %
No hantavirus vaccine is positioned for approval or broad availability by the end of 2026. All active candidates remain in preclinical or very early clinical stages, with no advanced human efficacy trials underway. Recent mRNA platforms, including single-dose candidates tested in hamsters at UTMB and work by Moderna with Korea University, have shown strong protection in rodent models against strains like Andes virus, yet these have not entered Phase 1 human testing. Older DNA vaccine efforts have completed limited Phase 1 safety studies but lack large-scale efficacy data or regulatory advancement. The 2026 cruise-ship outbreak has heightened awareness and prompted some funding discussions, yet development timelines for new vaccines—especially against regionally variable hantaviruses—typically span multiple years absent an extraordinary acceleration program. Realistic shifts before year-end would require unprecedented regulatory fast-tracking or emergency authorization based on preliminary data, scenarios viewed as improbable given current pipelines and resource constraints.
Reglas
Este mercado se resolverá a favor de "Sí" si alguna vacuna destinada a seres humanos y que inmunice contra el hantavirus (incluido el síndrome pulmonar por hantavirus (HPS) o el síndrome de fiebre hemorrágica con síndrome renal (HFRS)) recibe la aprobación completa de la Administración de Alimentos y Medicamentos de EE. UU. entre la creación del mercado y 31 de diciembre de 2026, 23:59 ET. De lo contrario, este mercado se resolverá como "No". La fuente principal para resolver este mercado será la información oficial de la FDA, incluida su lista de vacunas aprobadas (https://www.fda.gov/vaccines-blood-biologics/vaccines/vaccines-licensed-use-united-states); no obstante, también podrá utilizarse el consenso de fuentes periodísticas fiables.
Traducción automática. En caso de disputa, prevalece el original.